Allan M Jordan

List of Publications by Year in Descending Order

22 papers	2,607 citations	15 h-index	23 g-index
23 ext. papers	3,117 ext. citations	10.1 avg, IF	5.45 L-index

#	Paper	IF	Citations
22	and induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor. *Haematologica*, **2021**, 106, 1979-1987	6.6	22
21	Molecularly profiled trials: toward a framework of actions for the "nil actionables". *British Journal of Cancer*, **2021**, 125, 473-478	8.7	
20	Glucose 6-Phosphate Dehydrogenase from Trypanosomes: Selectivity for Steroids and Chemical Validation in Bloodstream. *Molecules*, **2021**, 26,	4.8	4
19	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. *Nature Cancer*, **2021**, 2, 1002-1017	15.4	3
18	Discovery of a Gatekeeper Residue in the C-Terminal Tail of the Extracellular Signal-Regulated Protein Kinase 5 (ERK5). *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
17	Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET Kinase. *ACS Medicinal Chemistry Letters*, **2020**, 11, 497-505	4.3	1
16	Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1. *ACS Omega*, **2019**, 4, 8892-8906	3.9	16
15	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. *Nature Medicine*, **2019**, 25, 738-743	50.5	119
14	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. *Cancer Research*, **2019**, 79, 4491-4502	10.1	18
13	Fluoromethylcyclopropylamine derivatives as potential in vivo toxicophores - A cautionary disclosure. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 560-562	2.9	2
12	Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. *Cell Reports*, **2018**, 22, 3641-3659	10.6	96
11	Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides. *Journal of Medicinal Chemistry*, **2018**, 61, 10767-10792	8.3	14
10	Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1. *Journal of Medicinal Chemistry*, **2017**, 60, 7984-7999	8.3	30
9	Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells. *Journal of Medicinal Chemistry*, **2016**, 59, 11120-11137	8.3	19
8	First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. *ACS Chemical Biology*, **2016**, 11, 3179-3190	4.9	73
7	Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. *Medicinal Research Reviews*, **2015**, 35, 586-618	14.4	101
6	Rethinking ‘academic’ drug discovery: the Manchester Institute perspective. *Drug Discovery Today*, **2015**, 20, 525-35	8.8	14

5	Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. *MedChemComm*, **2013**, 4, 1513	5	51
4	Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. *Journal of Medicinal Chemistry*, **2012**, 55, 4431-45	8.3	44
3	The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell*, **2012**, 21, 473-87	24.3	430
2	The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. *Journal of Medicinal Chemistry*, **2011**, 54, 3451-79	8.3	1494
1	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. *Nature Cancer*,	15.4	21